With CAR-T mar­ket­ing loom­ing, ear­ly study high­lights po­ten­tial of TCR en­gi­neer­ing

With the first gen­er­a­tion of CAR-Ts like­ly head­ed to a near-term ap­proval for blood can­cers, the clin­i­cal work on new adop­tive TCR-en­gi­neered cell ther­a­pies that can work in sol­id tu­mors is un­der­way.

This week, a re­search team led by the NIH’s Steven Rosen­berg — whose work has been used as a ba­sis of Kite Phar­ma’s pi­o­neer­ing CAR-T — rolled out ear­ly proof-of-con­cept da­ta from a small hu­man study us­ing a CD4+ T cell adapt­ed with a T cell re­cep­tor that ze­roes in on MAGEA3, or melanoma-as­so­ci­at­ed anti­gen A3.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER